Medios AG Reports Q1 2024 Revenue Growth, Reaffirms Full-Year Guidance

• Medios AG reported a 5.8% increase in revenue to €456.2 million in Q1 2024
• Cash flow from operating activities rose to €43.4 million
• The company confirmed its 2024 guidance, expecting a significant increase in revenue and margin
• Medios AG plans to close the acquisition of Ceban Pharmaceuticals B.V. in May 2024
• The Pharmaceutical Supply segment saw an 8.9% increase in revenue to €401.0 million in Q1 2024
• The Patient-Specific Therapies segment reported a revenue of €55.1 million in Q1 2024, a decrease from €62.9 million in the previous year.

The price of Medios at the time of the news was 14,070EUR and did not change compared to the previous day.
18 minutes after the article was published, the price was 14,200EUR this corresponds to a plus of +0,92 % since publication.

Medios

+0,71 %

-3,66 %

-0,98 %

-5,96 %

-19,13 %

-60,00 %

-16,47 %

+43,62 %

ISIN:DE000A1MMCC8WKN:A1MMCC

• Intraday
• 5 Tage
• 1 Monat
• 3M
• 1 Jahr
• 3J
• 5J
• Max